Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 81.55

-2.0%

Jan 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (4638)	3/28/2011 4:05:39 PM
From: Art Bechhoefer	Read Replies (1) of 4676

The list of clinical trials (and their dates) is very interesting because, despite promising results in many of the trials, the only drug that ISIS will be submitting for FDA approval in the near future appears to be mipomersen. We know from ISIS press releases and related news that mipomersen is being readied for submission some time in the second half of the year. Does this mean that the price of ISIS in the near future is contingent on a timely submission (no more delays) coupled with the ability of the company to keep its head above water in the interim? Art

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next